Primary Hyperparathyroidism during Pregnancy
Two Tales with Different Outcomes
DOI:
https://doi.org/10.15605/jafes.039.01.17Keywords:
endocrine disorders in pregnancy, primary hyperparathyroidism, pregnancy, hypercalcaemiaAbstract
Primary hyperparathyroidism (PHPT) is rare in pregnancy. This condition is challenging to diagnose and manage due to the limited diagnostic and therapeutic options that are safe during pregnancy. If not diagnosed and managed in a timely manner, serious maternal and foetal complications may occur. We report two cases, one with surgical intervention and one without, to show the importance of timely surgical intervention and discuss the challenges in the management of PHPT in pregnancy.
Downloads
References
Kort KC, Schiller HJ, Numann PJ. Hyperparathyroidism and pregnancy. Am J Surg. 1999;177(1):66-8. https://pubmed.ncbi.nlm.nih.gov/10037311. https://doi.org/10.1016/s0002-9610(98)00302-x.
Heath H 3rd, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302(4):189-93. https://pubmed.ncbi.nlm.nih.gov/7350459. https://doi.org/10.1056/NEJM198001243020402.
Shifrin A. Advances in diagnosis and management of primary hyperparathyroidism during pregnancy. Advances in treatment and management in surgical endocrinology. Elsevier Inc.; 2019.
Bollerslev J, Rejnmark L, Zahn A, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol. 2022;186(2):R33-63. https://pubmed.ncbi.nlm.nih.gov/34863037. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789028. https://doi.org/10.1530/EJE-21-1044.
Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165(6):851-64. https://pubmed.ncbi.nlm.nih.gov/21964961. https://doi.org/10.1530/EJE-11-0589.
Hassan-Smith ZK, Criseno S, Gittoes NJL. Mild primary hyperparathyroidism—to treat or not to treat? Br Med Bull. 2019;129(1):53-67. https://pubmed.ncbi.nlm.nih.gov/30576424. https://doi.org/10.1093/bmb/ldy042.
Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–9. https://pubmed.ncbi.nlm.nih.gov/19193908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214274. https://doi.org/10.1210/jc.2014-1413.
Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253(3):585-91. https://pubmed.ncbi.nlm.nih.gov/21183844. https://doi.org/10.1097/SLA.0b013e318208fed9.
Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab. 2009;22(8):741-9. https://pubmed.ncbi.nlm.nih.gov/19845125. https://doi.org/10.1515/jpem.2009.22.8.741.
Vera L, Oddo S, Di Iorgi N, Bentivoglio G, Giusti M. Primary hyperparathyroidism in pregnancy treated with cinacalcet: A case report and review of the literature. J Med Case Rep. 2016;10(1):361. https://pubmed.ncbi.nlm.nih.gov/27998296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175373. https://doi.org/10.1186/s13256-016-1093-2.
Arshad MF, Arambewela MH, Bennet WM, Sterrenburg M, Balasubramanian SP. Primary hyperparathyroidism in pregnancy: Experience of a tertiary centre. Surg Today. 2023;53(4):470-5. https://pubmed.ncbi.nlm.nih.gov/36107253. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042935. https://doi.org/10.1007/s00595-022-02583-8.
Rey E, Jacob C-E, Koolian M, Morin F. Hypercalcemia in pregnancy – a multifaceted challenge: Case reports and literature review. Clin Case Rep. 2016;4(10):1001-8. https://pubmed.ncbi.nlm.nih.gov/27761256. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054480. https://doi.org/10.1002/ccr3.646.
Joint Formulary Committee. Calcitonin (salmon). British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; [cited 2023 Feb 21]. https://bnf.nice.org.uk/drugs/calcitonin-salmon/.
Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30(12):1146-8. https://pubmed.ncbi.nlm.nih.gov/19175968. https://doi.org/10.1016/S1701-2163(16)34026-9.
Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68-73. https://pubmed.ncbi.nlm.nih.gov/10440778. https://doi.org/10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H.
DiMarco AN, Meeran K, Christakis I, et al. Seventeen cases of primary hyperparathyroidism in pregnancy: A call for management guidelines. J Endocr Soc. 2019;3(5):1009–21. https://pubmed.ncbi.nlm.nih.gov/31065618. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497920. https://doi.org/10.1210/js.2018-00340.
Hui E, Osakwe O, Teoh TG, Tolley N, Robinson S. Three case reports of maternal primary hyperparathyroidism in each trimester and a review of optimal management in pregnancy. Obstet Med. 2010;3(1):33–7. https://pubmed.ncbi.nlm.nih.gov/27582838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989765. https://doi.org/10.1258/om.2009.090040.
Schnatz PF, Thaxton S. Parathyroidectomy in the third trimester of pregnancy. Obstet Gynecol Surv. 2005;60(10):672–82. https://pubmed.ncbi.nlm.nih.gov/16186784. https://doi.org/10.1097/01.ogx.0000180889.23678.fb.
Norman J, Politz D, Politz L. Hyperparathyroidism during pregnancy and the effect of rising calcium on pregnancy loss: A call for earlier intervention. Clin Endocrinol (Oxf). 2009;71(1):104–9. https://pubmed.ncbi.nlm.nih.gov/19138316. https://doi.org/10.1111/j.1365-2265.2008.03495.x.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Yoon Dong Loh, Masliza Hanuni Mohd Ali
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.